Bombesin Receptor Subtype-3 (BRS3) Antibody

Background

Bombesin Receptor Subtype 3 (BRS3) is an orphan G-protein-coupled receptor within the bombesin receptor family, though its endogenous ligand remains unidentified. BRS3 is predominantly expressed in the central nervous system, including the hypothalamus, as well as in adipose tissue and certain peripheral organs. BRS3 is primarily involved in energy homeostasis and metabolic regulation, as it modulates thermogenesis, appetite control, and body weight. Activation of BRS3 increases energy expenditure by stimulating pathways in brown adipose tissue, enhancing heat production and combating obesity. In addition to energy regulation, BRS3 influences glucose metabolism and insulin sensitivity, suggesting potential roles in type 2 diabetes treatment. Furthermore, BRS3 signaling regulates blood pressure, contributing to cardiovascular homeostasis. Dysregulation of BRS3 expression has been linked to obesity, metabolic syndrome, and certain cancers, particularly lung cancer and prostate cancer, where it may facilitate tumor proliferation and survival. Given its critical roles in metabolism, thermogenesis, and cancer biology, BRS3 has emerged as a potential therapeutic target for metabolic diseases and oncology. Ongoing studies aim to identify its natural ligand and develop pharmacological agonists or antagonists to exploit its therapeutic potential.